1. Home
  2. PRPL vs SKYE Comparison

PRPL vs SKYE Comparison

Compare PRPL & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Purple Innovation Inc.

PRPL

Purple Innovation Inc.

HOLD

Current Price

$0.60

Market Cap

76.9M

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$0.62

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRPL
SKYE
Founded
2010
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
76.9M
44.9M
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
PRPL
SKYE
Price
$0.60
$0.62
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$1.00
$14.75
AVG Volume (30 Days)
178.3K
286.5K
Earning Date
05-05-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
22.22
N/A
EPS
0.45
N/A
Revenue
$487,877,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$12.69
N/A
P/E Ratio
$1.52
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.56
$0.62
52 Week High
$1.26
$5.75

Technical Indicators

Market Signals
Indicator
PRPL
SKYE
Relative Strength Index (RSI) 32.77 36.73
Support Level N/A N/A
Resistance Level $0.84 $0.83
Average True Range (ATR) 0.04 0.05
MACD -0.01 -0.00
Stochastic Oscillator 2.31 4.28

Price Performance

Historical Comparison
PRPL
SKYE

About PRPL Purple Innovation Inc.

Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms and other products. The Company has one reportable segment that operates an omni-channel distribution which allows the Company to offer a seamless shopping experience to its customers across multiple sales channels. It sells its products through its direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: